Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Aug 23, 2018
Pfizer: Lots of Moving Parts in a Generally-Inspiring Second Quarter
Image Source: Pfizer. We came away generally impressed with the progress at Pfizer during the second quarter as the company begins to replace its current patent protected line-up with next-generation treatments. Pfizer continues to gain political favor with its decision to forgo price hikes on its product line-up while announcing a re-organization of the business structure.
Jan 13, 2016
You Loved This One: A Little Inspiration
“Whether you think you can, or you think you can't -- you're right.” ― Henry Ford
Oct 29, 2013
Pfizer’s and Merck’s 3Q Performance
Let’s take a look at fundamental performance of Pfizer and Merck during the third quarter.
Aug 1, 2013
Pfizer and Merck Show Revenue Declines; Pipelines Remain Strong
Pfizer and Merck faced key patent expirations in the second quarter. However, both of their respective pipelines are promising.
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.